162 related articles for article (PubMed ID: 37878888)
1. A bioinformatic analysis of the role of TP53 status on the infiltration of CD8+ T cells into the tumor microenvironment.
El-Arabey AA; Abdel-Hamied HE; Awadalla ME; Alosaimi B; Almanaa TN; Al-Shouli ST; Modafer YA; Alhamdi HW; Abdalla M
Braz J Med Biol Res; 2023; 56():e12970. PubMed ID: 37878888
[TBL] [Abstract][Full Text] [Related]
2. SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors.
El-Arabey AA; Abdalla M; Abd-Allah AR
Int Immunopharmacol; 2020 Sep; 86():106758. PubMed ID: 32663767
[TBL] [Abstract][Full Text] [Related]
3. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
5. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
7. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
8. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
9. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
10.
Shi Y; Ren X; Cao S; Chen X; Yuan B; Brasil da Costa FH; Rodriguez Rosario AE; Corona A; Michikawa C; Veeramachaneni R; Osman AA; Xie T; Wang W; Sikora AG; Myers JN; Rangel R
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604640
[TBL] [Abstract][Full Text] [Related]
11. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma.
Song X; Chen Q; Wang J; Mao Q; Xia W; Xu L; Jiang F; Dong G
J Cell Mol Med; 2022 Jan; 26(2):436-448. PubMed ID: 34877770
[TBL] [Abstract][Full Text] [Related]
13. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
14. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
16. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
Front Immunol; 2022; 13():876355. PubMed ID: 35837383
[TBL] [Abstract][Full Text] [Related]
17. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
18. A
Xu F; Lin H; He P; He L; Chen J; Lin L; Chen Y
Oncoimmunology; 2020; 9(1):1731943. PubMed ID: 32158625
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.
Knebel M; Körner S; Kühn JP; Wemmert S; Brust L; Smola S; Wagner M; Bohle RM; Morris LGT; Pandey A; Schick B; Linxweiler M
Front Immunol; 2023; 14():1172768. PubMed ID: 37383237
[TBL] [Abstract][Full Text] [Related]
20. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.
Sial N; Ahmad M; Hussain MS; Iqbal MJ; Hameed Y; Khan M; Abbas M; Asif R; Rehman JU; Atif M; Khan MR; Hameed Z; Saeed H; Tanveer R; Saeed S; Sharif A; Asif HM
Sci Rep; 2021 Oct; 11(1):19873. PubMed ID: 34615943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
